Compare Freshworks Inc (FRSH) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance

Freshworks (FRSH) trades at $13.69, down 1.65% on the day, with a bullish technical signal and strong fundamental momentum. The company achieved GAAP profitability in Q2 2026, with revenue growth of 16% year-over-year and a net income margin of 20.49%. Analyst consensus is split evenly between Buy and Hold, with a price target of $14.60, suggesting modest upside from current levels. Recent news highlights AI adoption and enterprise growth as key drivers.

The outlook for FRSH is positive, supported by sustained revenue growth, improving profitability, and strategic focus on AI and employee experience products. Risks include competitive pressures in the SaaS sector and execution challenges in maintaining growth momentum. The stock presents an opportunity for investors seeking exposure to a profitable, growing software company with a reasonable valuation.

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.